FAQ/Help |
Calendar |
Search |
Today's Posts |
05-26-2011, 07:44 AM | #1 | |||
|
||||
Senior Member
|
http://www.genengnews.com/gen-news-h...ases/81245205/
Elan is making a $20 million equity investment in U.S. firm Proteostasis Therapeutics as part of a drug discovery partnership focused on neurodegenerative and dementia-related disorders including Parkinson disease, Huntington disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer disease. .. Proteostasis is developing a class of small molecule therapeutics known as proteostasis regulators for treating neurodegenerative, metabolic, genetic, and inflammatory disorders. The candidates are designed to correct perturbed signalling pathways in disease, and restore the correct interaction of the network of proteins controlled by known biological signalling pathways and processes that control protein folding, trafficking, and clearance, which are collectively known as the proteostasis network.
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Unfolding amyloid secrets & misfolding of abnormal proteins | Parkinson's Disease | |||
Small molecules found to protect cells in multiple models of Parkinson's disease | Parkinson's Disease | |||
Immune Molecules Prune Synapses in Developing Brain | Parkinson's Disease | |||
Molecules of emotion.... | Bipolar Disorder |